Fennec Pharmaceuticals Inc.
corporate_fare Company Profile
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 19 items for FENC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for FENC spans 10-Q, 8-K, DEF 14A, 10-K.
Recent high-impact activity:
- Fennec Q3 2026: Net Product Sales Up 56% to $19.4M, Net Income $4.6M
- Fennec Posts $5.8M Q3 Adjusted EBITDA as PEDMARK Sales Scale
- PEDMARK Phase 2 STS-J01: 24% Hearing Loss vs 56.4% Benchmark and 95.8% Tumor Response
- PEDMARK Phase 2 Cuts Hearing Loss to 24% vs 56% Benchmark
- Fennec Q2 Sales Jump 78% to $17.1M, Swings to Profit
Financial Snapshot
Short Interest & Short Volume
3.89 days to coverFINRA reported short interest of 454,453 shares in FENC as of the October 30, 2026 settlement, a 6.8% decrease from the prior period — about 3.9 days to cover at its recent average daily volume. On November 20, 2026, 27.7% of FENC volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.